Our COVID-19 Hub includes a Directory of Companies Developing COVID-19 Therapies, a searchable listing of relevant Clinical Trials and Expanded Access Opportunities culled from ClinicalTrials.gov, and links to the latest FDA, CDC, and NIH updates. In addition to medical interventions, the COVID-19 Hub also links to critical FDA resources for consumers and industry focused on food and veterinary safety.
Through IMEDS, the FDA Foundation provides access to FDA-quality data to facilitate the analyses of medical product safety evaluations for private-sector entities, such as regulated industry, academic institutions, and non-profit organizations.
The IMEDS Network engages a subset of the FDA’s Sentinel Network as a national resource for broader public health and medical evidence generation.
IMEDS facilitates studies that increase understanding of the real-world safety and effectiveness of pharmacologic therapies.
…
The Expanded Access Navigator, or EA Navigator, represents a unique partnership between the Reagan-Udall Foundation for the FDA, patient advocacy organizations, the pharmaceutical industry, and the federal government to provide clear, digestible information on single-patient EA.
Food plays a significant role in public health, from the quality and safety of the food supply to the nutrition it provides. Nutrition-related chronic diseases, such as heart disease and cancer, are the leading cause of death and disability in the United States. Nearly one in three adults in the U.S. have high blood pressure, which can lead to heart disease and strokes, and 13 percent have diabetes. A staggering 70 percent of U.S. adults are overweight, with roughly 40 percent classified as obese. Among children and adolescents, almost one in five are obese.…
Big Data For Patients (BD4P), a replicable training program, gives patient advocates a basic understanding of the science and enables full and effective participation in big data initiatives. Developed with multiple stakeholder groups, the program includes tools and best practices accessible on this site.
FDA Patient Listening Sessions are one way patient communities and FDA staff connect about the experiences of living with specific diseases and conditions. The Reagan-Udall Foundation works closely with the Patient Affairs team in FDA’s Office of Clinical Policy and Programs/Office of the Commissioner to conduct these small, informal discussions. Patients, caregivers, and advocates provide personal insight into the day-to-day challenges of living with a specific disease with staff from FDA’s medical products centers: Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health.